Participant flow

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma · Source last updated 2019-08-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Starting Dose Level 1= 0.15 mg/kg\> Each cycle is 4 weeks.\> \> Cycle 1 and 2:\> Alefacept by IV Weekly\> \> Cycles 3-12:\> Alefacept by IV 1 x every 4 weeks

   id

   FG000

   title

   Dose Level 1

2. description

   Starting Dose Level 1= 0.20 mg/kg\> Each cycle is 4 weeks.\> \> Cycle 1 and 2:\> Alefacept by IV Weekly\> \> Cycles 3-12:\> Alefacept by IV 1 x every 4 weeks

   id

   FG001

   title

   Dose Level 2

3. description

   Starting Dose Level 1= 0.30 mg/kg\> Each cycle is 4 weeks.\> \> Cycle 1 and 2:\> Alefacept by IV Weekly\> \> Cycles 3-12:\> Alefacept by IV 1 x every 4 weeks

   id

   FG002

   title

   Dose Level 3

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         8

      3. group Id

         FG002

         num Subjects

         9

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         8

      3. group Id

         FG002

         num Subjects

         9

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice